Quizartinib

奎扎替尼

Report date: 2025/01/20 16:57:46
NME

Base Information

Drug NameQuizartinib
Drug Alias Name盐酸奎扎替尼Quizartinib HydrochlorideVanflytaAC-010220ASP-2689 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsGranulocyte-macrophage colony-stimulating factor receptor antagonists
TargetsTyrosine-protein kinase receptor FLT3Granulocyte-macrophage colony-stimulating factor receptor
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesHepatic Insufficiency +[8] 
Global Approved IndicationsLeukemia, Myeloid, AcuteLeukemia, Myeloid
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2019/06/18
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesAmbit Biosciences Co
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo (China) Holdings Co LtdDaiichi Sankyo Europe GmbhDaiichi Sankyo Inc +[6] 
Inactive CompaniesAmbit Biosciences CoCardiff UniversityThe University Of Hong Kong
Active IndicationsMyelodysplastic SyndromesHepatic InsufficiencyLeukemia, Myelomonocytic, Chronic +[6] 
Inactive IndicationsSolid tumoursPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeL01EX11
Related LinksWikipediaDrugBankKEGG